ReviewPharmaceuticals (Basel, Switzerland)2025
Advancements in Polysaccharide-Based Nanoparticles for the Treatment of Breast Cancer: A Comprehensive Review.
Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Statistical optimization of Chlorella vulgaris polysaccharides-mediated synthesis of platinum nanoparticles with dual functions: anticancer and anticoagulant activities.Microbial cell factories · 2026Article
- Glucan-Based Nanoparticles Empower Precision Cancer Immunotherapy: Design Strategies, Immune Reprogramming Mechanisms, and Clinical Translation Prospects.International journal of nanomedicine · 2026Review
- Polysaccharide-based anticancer therapeutics: molecular mechanisms, translational advances, and the road toward precision oncology.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Breast cancer is a significant global health challenge, with rising incidence rates and substantial morbidity and mortality worldwide. Conventional treatments, while effective, often lead to adverse effects and may not fully eradicate cancer cells, resulting in recurrence and progression of tumors. Addressing these challenges requires innovative treatment strategies. Nanotechnology, particularly polysaccharide-based nanoparticles (NPs), offers a promising approach due to their biocompatibility, tunable properties, and targeted drug delivery capabilities. Polysaccharide NPs, including starch, alginate, hyaluronic acid, and chitosan, possess inherent biocompatibility and can be tailored for specific applications. Furthermore, beyond their inherent biocompatibility, polysaccharide-based NPs shown substantial interest due to their natural abundance, ease of processing, and availability from renewable resources, solidifying their role as a sustainable choice for diverse biomedical applications. By functionalizing their surface with ligands, polysaccharide NPs can target breast cancer cells, enhance therapeutic efficacy while minimizing off-target effects. Moreover, these NPs can modulate biological processes relevant to cancer progression, such as angiogenesis and immune response. This review article provides a concise overview of the pathophysiology of breast cancer and the benefits of polysaccharides in drug delivery. Additionally, it emphasizes the significance of several polysaccharide-based NPs in breast cancer therapy, followed by a detailed discussion on the role of various polysaccharide-based NPs in breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.